Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
REGENEUS executive chairman John Martin blanches at suggestions the regenerative medicine minnow is a poor man's alternative to stem-cell play Mesoblast, which commands a $1.9 billion market valuation. "We are not a poor man's anyone -- we have our own story," Mr Martin said, adding "There's no doubt Mesoblast has done a good job priming the Australian market about stem-cell therapies." In the first non-device biotech listing in more than two years, Regeneus principals are seeking to raise $10 million in an IPO, valuing the Sydney-based human and veterinary therapy outfit at $45m.
Help employers find you! Check out all the jobs and post your resume.
REGENEUS executive chairman John Martin blanches at suggestions the regenerative medicine minnow is a poor man's alternative to stem-cell play Mesoblast, which commands a $1.9 billion market valuation. "We are not a poor man's anyone -- we have our own story," Mr Martin said, adding "There's no doubt Mesoblast has done a good job priming the Australian market about stem-cell therapies." In the first non-device biotech listing in more than two years, Regeneus principals are seeking to raise $10 million in an IPO, valuing the Sydney-based human and veterinary therapy outfit at $45m.
Help employers find you! Check out all the jobs and post your resume.
